explore -WSS

explore

author：comprehensive 2025-10-04 08:14:23 - browse：96

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Cholera vaccine supplies dangerously low, outbreaks surging

WSS

Ford recalls 870K F

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Biden to sign 'historic' executive order on how US military handles sexual assault cases

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Redefining sustainability for the pharmaceutical industry

leisure time

explore

leisure time

Jerome Adams on the need for new antivirals for Covid

Children’s Hospital revives plan for pedestrian bridge

Malaria cases in Florida and Texas: Here’s what you need to know

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Virginia high school admissions case could be legal follow

Ford recalls 870K F

Duchenne breakthrough therapy leaves behind pioneering families

Timeline: Special counsel's probe into Trump's handling of classified documents

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

explore

Stoke drug shows lower activity against childhood epilepsy

Biden announces an advanced cancer research initiative

'The boss' wants server deleted: New allegations emerge in Trump indictment

Behind warning on Apellis’s eye drug lies a conflict of interest

Redefining sustainability for the pharmaceutical industry

Biden jokes that Republicans may impeach him because inflation is starting to cool down

leisure time

explore

hotspot

focus